.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Queensland Health
Chinese Patent Office
Deloitte
Chubb
Daiichi Sankyo
Boehringer Ingelheim
US Army
UBS
Julphar

Generated: June 22, 2017

DrugPatentWatch Database Preview

Naloxegol oxalate - Generic Drug Details

« Back to Dashboard

What are the generic sources for naloxegol oxalate and what is the scope of naloxegol oxalate freedom to operate?

Naloxegol oxalate
is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naloxegol oxalate has eighty-eight patent family members in thirty-seven countries.

Three suppliers are listed for this compound.

Summary for Generic Name: naloxegol oxalate

Tradenames:1
Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Clinical Trials: see list68
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:naloxegol oxalate at DailyMed

Pharmacology for Ingredient: naloxegol oxalate

Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-002Sep 16, 2014RXYesYes7,662,365► SubscribeYY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-002Sep 16, 2014RXYesYes7,786,133► SubscribeYY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo7,662,365► SubscribeYY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-001Sep 16, 2014RXYesNo7,786,133► SubscribeYY ► Subscribe
Astrazeneca Pharms
MOVANTIK
naloxegol oxalate
TABLET;ORAL204760-002Sep 16, 2014RXYesYes8,067,431► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: naloxegol oxalate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,149,539Crystalline naloxol-PEG conjugate► Subscribe
2,015,197,470► Subscribe
8,349,307Polymer conjugates of opioid antagonists► Subscribe
9,388,104Chemically modified small molecules► Subscribe
8,034,825Chemically modified small molecules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: naloxegol oxalate

Country Document Number Estimated Expiration
Portugal2939696► Subscribe
Australia2011307608► Subscribe
European Patent Office2992903► Subscribe
Colombia6700851► Subscribe
World Intellectual Property Organization (WIPO)2012044243► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NALOXEGOL OXALATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0037France► SubscribePRODUCT NAME: NALOXEGOL OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER L'OXALATE DE NALOXEGOL; REGISTRATION NO/DATE: EU/1/14/962 20141210
0737Netherlands► SubscribePRODUCT NAME: NALOXEGOL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER NALOGEXOLOXALAAT; REGISTRATION NO/DATE: EU/1/14/962 20141210
2015 00028Denmark► SubscribePRODUCT NAME: OXYLATSALT AF NALOXEGOL; REG. NO/DATE: EU/1/14/962 20141208
2015000037Germany► SubscribePRODUCT NAME: NALOXEGOL ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/962 20141208
/2015Austria► SubscribePRODUCT NAME: NALOXEGOL, GEGEBENENFALLS IN FORM EINES THERAPEUTISCH VERTRAEGLICHEN SALZES, INSBESONDERE ALS OXALAT; REGISTRATION NO/DATE: EU/1/14/962 20141208
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Cerilliant
Farmers Insurance
Argus Health
Mallinckrodt
Chinese Patent Office
Cipla
Johnson and Johnson
UBS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot